Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 1246 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018;175:enero. [Ref.ID 102495]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees . JAMA Intern Med 2018:2 de abril. [Ref.ID 102494]
4. Cita con resumen
6. Cita con resumen
Mir de Francia R. Los fabricantes de opioides fijan a España como nuevo mercado. eldiario.es 2018:1. [Ref.ID 102452]
8.Tiene citas relacionadas Cita con resumen
Kyriacou DN. Opioid vs nonopioid acute pain management in the emergency department. JAMA 2017;318:1655-6. [Ref.ID 102136]
9.Tiene citas relacionadas Cita con resumen
Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ 2017;359:j4792. [Ref.ID 102106]
10. Cita con resumen
Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]
11. Cita con resumen
Lee-HY, Ban G-Y, Jeong C-G, Lee JH, Park SH, Kim SH, Lee Y-H, Ye Y-M. Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiol Drug Saf 2017;26:256-64. [Ref.ID 102062]
12. Cita con resumen
Schuchat A, Houry D, Guy Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6. [Ref.ID 102055]
13. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
15. Cita con resumen
Becker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a global opioid crisis. BMJ 2017;358:j3115. [Ref.ID 102015]
16. Cita con resumen
Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 2017;73:105-13. [Ref.ID 101939]
17. Cita con resumen
Makris UE, Alvarez CA, Wei W, Mortensen EM, Mansi IA. Association of statin use with risk of back disorder diagnoses. JAMA Intern Med 2017;177:julio. [Ref.ID 101673]
18.Tiene citas relacionadas Cita con resumen
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017;390:8 de julio. [Ref.ID 101669]
19. Cita con resumen
Guy Jr GP, Zhang K, Bohm MK, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704. [Ref.ID 101665]
20. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
Seleccionar todas
 
 1 a 20 de 1246 siguiente >>